Daewoong BTX's 'Nusiba' Continues European Expansion with Launch in Italy

Daewoong Pharmaceutical announced on the 30th that its botulinum toxin (BTX) 'Nusiba' (domestic name Nabota) was recently officially launched in Italy through its advanced beauty indication partner, Evolus.

Daewoong Pharmaceutical's botulinum toxin (BTX) 'Nusiba' (domestic name Nabota)
[Photo by Daewoong Pharmaceutical]

Italy is the fourth European country where Daewoong Pharmaceutical's Nusiba has entered, following the UK, Germany, and Austria. According to the global market research firm Fortune Business Insights (FBI), Italy ranks fourth in the European BTX market, which is worth 650 billion KRW annually, with the market size estimated to reach 78 billion KRW this year.

Evolus, the partner responsible for the distribution and marketing of Nusiba in Italy, has formed a strategic partnership with GP Derma Solution, a local specialist distributor in the beauty and wellness sector, to prepare for the local launch. They plan to start product marketing activities and educational programs targeting local medical professionals soon, and will provide an online platform capable of virtual training to help Italian medical staff learn the procedure, ultimately aiming to enhance customer satisfaction.

Evolus plans to utilize extensive real-world data (RWD) accumulated from North American and European markets to ensure that Italian customers can achieve natural results through Nusiba treatments.

Park Sung-soo, Vice President of Daewoong Pharmaceutical, stated, “It is encouraging that Nusiba’s brand awareness and presence in Europe have been further strengthened as we sequentially launched in the UK, Germany, Austria, and now Italy.” He added, “We look forward to Daewoong Pharmaceutical’s BTX making significant strides in the two major global markets of North America and Europe.”

This content was produced with the assistance of AI translation services.